Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions... Show more
The Moving Average Convergence Divergence (MACD) for IXHL turned positive on October 28, 2025. Looking at past instances where IXHL's MACD turned positive, the stock continued to rise in of 32 cases over the following month. The odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 46 cases where IXHL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IXHL advanced for three days, in of 181 cases, the price rose further within the following month. The odds of a continued upward trend are .
IXHL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 19, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on IXHL as a result. In of 54 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IXHL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for IXHL entered a downward trend on November 26, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IXHL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.605) is normal, around the industry mean (16.589). P/E Ratio (0.000) is within average values for comparable stocks, (73.316). IXHL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.951). IXHL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). IXHL's P/S Ratio (3333.333) is very high in comparison to the industry average of (55.567).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IXHL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Industry PharmaceuticalsGeneric
A.I.dvisor tells us that IXHL and INM have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IXHL and INM's prices will move in lockstep.
| Ticker / NAME | Correlation To IXHL | 1D Price Change % | ||
|---|---|---|---|---|
| IXHL | 100% | +7.11% | ||
| INM - IXHL | 25% Poorly correlated | -5.71% | ||
| ESPR - IXHL | 23% Poorly correlated | +7.05% | ||
| NBIX - IXHL | 22% Poorly correlated | +5.64% | ||
| HROW - IXHL | 22% Poorly correlated | +0.73% | ||
| YCBD - IXHL | 20% Poorly correlated | -3.44% | ||
More | ||||
| Ticker / NAME | Correlation To IXHL | 1D Price Change % |
|---|---|---|
| IXHL | 100% | +7.11% |
| Pharmaceuticals: Generic industry (213 stocks) | -8% Poorly correlated | +1.93% |